Comment diagnostiquer une inhibition enzymatique ?

Des tests sanguins et des analyses biochimiques évaluent l'activité enzymatique.

Quels symptômes indiquent une inhibition enzymatique ?

Des symptômes comme la fatigue, la douleur abdominale ou des troubles digestifs peuvent apparaître.

Quels tests sont utilisés pour détecter les antienzymes ?

Les tests d'activité enzymatique et les dosages spécifiques d'anticorps sont courants.

Peut-on utiliser l'imagerie pour diagnostiquer ?

L'imagerie peut aider à évaluer les organes affectés, mais n'est pas spécifique aux antienzymes.

Quels marqueurs biochimiques sont associés aux antienzymes ?

Les niveaux d'enzymes spécifiques dans le sang peuvent indiquer une inhibition enzymatique.

Quels sont les symptômes d'une inhibition enzymatique ?

Les symptômes incluent douleurs abdominales, nausées, et troubles métaboliques.

L'inhibition enzymatique peut-elle causer des douleurs ?

Oui, elle peut entraîner des douleurs dues à des troubles digestifs ou métaboliques.

Y a-t-il des symptômes spécifiques selon l'enzyme inhibée ?

Oui, les symptômes varient selon l'enzyme affectée, comme la lactase ou la lipase.

Les symptômes sont-ils toujours présents ?

Non, certains patients peuvent être asymptomatiques malgré une inhibition enzymatique.

Comment les symptômes évoluent-ils avec le temps ?

Les symptômes peuvent s'aggraver si l'inhibition persiste sans traitement approprié.

Comment prévenir l'inhibition enzymatique ?

Une alimentation équilibrée et l'évitement de substances toxiques peuvent aider.

Les vaccinations peuvent-elles prévenir des inhibitions enzymatiques ?

Certaines vaccinations peuvent prévenir des infections qui causent des inhibitions enzymatiques.

Y a-t-il des habitudes de vie à adopter ?

Oui, éviter l'alcool et le tabac peut réduire le risque d'inhibition enzymatique.

Les contrôles médicaux réguliers sont-ils importants ?

Oui, des contrôles réguliers permettent de détecter précocement des problèmes enzymatiques.

L'éducation sur les médicaments est-elle nécessaire ?

Oui, comprendre les effets des médicaments aide à prévenir les inhibitions enzymatiques.

Quels traitements existent pour l'inhibition enzymatique ?

Les traitements incluent des médicaments spécifiques et des modifications diététiques.

Les antienzymes sont-ils utilisés en chimiothérapie ?

Oui, certains antienzymes sont utilisés pour cibler des enzymes dans les cellules cancéreuses.

Comment les inhibiteurs enzymatiques sont-ils administrés ?

Ils peuvent être administrés par voie orale, intraveineuse ou topique selon le cas.

Y a-t-il des effets secondaires aux antienzymes ?

Oui, des effets secondaires comme des nausées, des éruptions cutanées ou des douleurs peuvent survenir.

Les traitements sont-ils personnalisés ?

Oui, le traitement est souvent adapté en fonction de la cause et de la gravité de l'inhibition.

Quelles complications peuvent survenir avec l'inhibition enzymatique ?

Des complications comme des troubles métaboliques ou des maladies organiques peuvent survenir.

L'inhibition enzymatique peut-elle entraîner des maladies chroniques ?

Oui, une inhibition prolongée peut contribuer à des maladies chroniques comme le diabète.

Y a-t-il des risques de surdosage avec les antienzymes ?

Oui, un surdosage peut entraîner des effets indésirables graves et des complications.

Comment gérer les complications liées aux antienzymes ?

La gestion implique un suivi médical régulier et des ajustements de traitement.

Les complications sont-elles réversibles ?

Certaines complications peuvent être réversibles avec un traitement approprié et rapide.

Quels sont les facteurs de risque d'inhibition enzymatique ?

Les facteurs incluent des antécédents familiaux, des maladies héréditaires et des habitudes alimentaires.

L'âge influence-t-il le risque d'inhibition enzymatique ?

Oui, le risque augmente souvent avec l'âge en raison de la dégradation enzymatique naturelle.

Les maladies auto-immunes sont-elles un facteur de risque ?

Oui, certaines maladies auto-immunes peuvent augmenter le risque d'inhibition enzymatique.

Le mode de vie affecte-t-il le risque ?

Oui, un mode de vie sédentaire et une mauvaise alimentation augmentent le risque.

Les médicaments peuvent-ils être des facteurs de risque ?

Oui, certains médicaments peuvent interférer avec l'activité enzymatique et augmenter le risque.

Antienzymes - Informations médicales vérifiées

A method based on plateletpheresis to obtain functional platelet, CD3

10 2022

DOI: 10.1111/cea.14192 PMID: 35757844

In previous studies with peripheral blood cells, platelet factors were found to be associated with severe allergic phenotypes. A reliable method yielding highly concentrated and pure platelet samples ... Twenty-seven subjects were voluntarily subjected to plateletpheresis. PRP, PPP and blood cell concentrate contained in a leukocyte reduction system chamber (LRSC) were obtained in this process. CD3... A reliable high yield method to obtain matched samples of PRP, PPP, CD3... We have developed a method that yields not only high content and pure platelet samples from a single donor but also CD3...

Blood Platelets Leukocytes Plateletpheresis RNA

A multivariate analysis of the risk of iron deficiency in plateletpheresis donors based on logistic regression.

Feb 2023

DOI: 10.1016/j.transci.2022.103522 PMID: 35985968

The purpose of this study was to analyze the application of individual factors, blood cell related indicators, and blood donation frequency in predicting the risk of iron deficiency of plateletpheresi... A total of 801 plateletpheresis donors were included in this study. The relationship between risk factors and iron deficiency was retrospectively analyzed by univariate analysis and logistic regressio... The rate of iron deficiency in this study was 31.5 % (241/766). The age, gender (the ratio of male donors), red blood cell related indicators, blood donation frequency were statistically different bet... Age, gender, the reciprocal of Hb and MCHC, RDV-CV, blood donation frequency are associated with the risk of iron deficiency in plateletpheresis donors. The combination of these indicators has high va...

Humans Male Iron Plateletpheresis Ferritins +5 autres

COVID-19 vaccine humoral response in frequent platelet donors with plateletpheresis-associated lymphopenia.

09 2022

DOI: 10.1111/trf.17037 PMID: 35919021

Plateletpheresis involves platelet separation and collection from whole blood while other blood cells are returned to the donor. Because platelets are replaced faster than red blood cells, as many as ... We assessed vaccine responses following 2 doses of COVID-19 vaccination in a cohort of 43 plateletpheresis donors with a range of pre-vaccination CD4... Participants were stratified into two groups: <400 CD4/μl (n = 27) and ≥ 400 CD4/μl (n = 16). Following the first dose, 79% seroconverted within the <400 CD4/μl group compared to 87% in the ≥400 CD4/μ... Overall, our results indicate that lymphopenic plateletpheresis donors do not exhibit significant immune dysfunction; they have retained the T and B cell functionality necessary for potent antibody re...

Blood Donors COVID-19 COVID-19 Vaccines Humans Lymphopenia +2 autres

Efficacy of autologous plateletpheresis in adult aortic surgery: study protocol for a randomised controlled trial.

07 06 2023

DOI: 10.1136/bmjopen-2023-073341 PMID: 37286322

Perioperative coagulopathy is common in patients undergoing aortic surgery, increasing the risk of excessive blood loss and subsequent allogeneic transfusion. Blood conservation has become a vital par... This is a prospective, single-centre, single-blind randomised controlled trial. A total of 344 adult patients undergoing aortic surgery with CPB will be enrolled and randomised to either the APC group... This study was approved by the institutional review board of Fuwai Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College (no. 2022-1806). All procedures included in this study... Chinese Clinical Trial Register (ChiCTR2200065834)....

Humans Adult Plateletpheresis Prospective Studies Single-Blind Method +3 autres

Plateletpheresis donor deferral patterns at a tertiary care hospital in North India: A need for rethink of haemoglobin cutoff.

May 2023

DOI: 10.1016/j.tracli.2023.02.006 PMID: 36893913

The donor deferral criteria for blood or apheresis donations are established for two main reasons: (i) to ensure the safety of the blood donor (non-maleficence); (ii) to obtain safe blood of standard ... The present study was conducted from May 2021 till June 2022 in the department of transfusion medicine of a tertiary care hospital in North India. The first part of the study was conducted from May 20... During the study period, a total of 260 donors were screened for plateletpheresis, out of which 221 (85%) donors were accepted and 39 (15%) donors were deferred for various reasons. Out of the 39 defe... Low haemoglobin (<12.5 g/dl) is a significant cause of temporary plateletpheresis donor deferral in India. In view of the advancement in plateletpheresis technology, which has resulted in minimal red ...

Humans Plateletpheresis Tertiary Care Centers Blood Donors Hemoglobins +1 autres

Prevalence and causes of pre-donation deferrals among potential plateletpheresis donors at a blood center in Eastern China.

May 2023

DOI: 10.1016/j.tracli.2022.10.004 PMID: 36257581

In China, the platelet donation interval is 14 days. The eligibility criterion of plateletpheresis donors (PD) is more stringent than that of whole blood donors, so the deferral causes are very compli... To analyse the deferral prevalence and influencing factors during pre-donation among PDs in a blood centre in Eastern China.... From December 26, 2020 to December 25, 2021, all data of potential PDs during pre-donation were extracted from the register system and collected using Microsoft Excel. The number of deferred visits an... A total of 19,762 visits were included in the study. Of these 17,847 (90.3%) donated platelets successfully and 1915 (9.7%) were deferred. The prevalence of deferrals was high among those less than 35... The deferral prevalence in Chinese plateletpheresis donors was not high. First-time and young donors were more frequently deferred. The repeat donors should be of concern, especially with abnormal hae...

Humans Adult Retrospective Studies Plateletpheresis Prevalence +2 autres

'Ironing out the risk': Assessing the effect of plateletpheresis donation frequency on iron stores in South-Asian male donors.

Nov 2023

DOI: 10.1111/vox.13525 PMID: 37772675

Repeated blood donation is a well-known cause of iron deficiency among donors. However, present scientific literature lacks comprehensive evidence regarding the impact of regular plateletpheresis proc... A total of 180 male participants from our platelet donor registry were enrolled in this observational cross-sectional study. Enrolment questionnaires were administered to eligible donors, and biologic... Donors with ≥12 donations per year showed the highest prevalence of low ferritin (serum ferritin: 15-30 ng/mL) and absent iron stores (serum ferritin <15 ng/mL) (41.3% and 26.7%, respectively). Ferrit... Regular plateletpheresis donations can lead to varying severities of non-anaemic iron deficiency. Blood centres must regularly monitor frequent plateletpheresis donors (especially donors with more tha...

Humans Male Iron Plateletpheresis Blood Donors +3 autres

Decreased levels of ferritin, mild thrombocytosis, and increased erythropoietin are sequential events among frequent plateletpheresis donors: Implication for a ferritin screen.

Dec 2022

DOI: 10.1016/j.transci.2022.103501 PMID: 35835689

It is generally recognized that repeat apheresis increases the risk for iron deficiency, thus may impact on the blood homeostasis. With regard to donor vigilance, we clarified the mid- to long-term ef... Levels of erythropoietin (EPO), hemoglobin (Hb) and ferritin were analyzed in double-unit (500 mL whole blood or 6 × 10... Regardless of the donation experience in whole blood or plateletpheresis, iron deficiency (serum ferritin concentrations <15 μg/L) was identified in all earnest cohorts. The ferritin means were signif... Regular ferritin screens are crucial to ensure a high level of donor health protection....

Male Humans Plateletpheresis Ferritins Blood Donors +3 autres

Determinants of Variable Total Platelet Count in Healthy Plateletpheresis Donor.

Jul 2024

DOI: 10.1007/s12288-023-01721-7 PMID: 39011268

The platelet count in a healthy individual varies between 150 and 450 × 10...

In vitro storage characteristics of neonatal platelet concentrates after addition of 20% PAS-E.

Oct 2022

DOI: 10.1111/vox.13345 PMID: 36222157

An observed decline in end-of-storage pH in plateletpheresis-derived platelet concentrates for neonatal use suspended in 100% autologous plasma was expected to be reversed by the addition of a platele... For each replicate, one of a pair from a double adult dose plateletpheresis collection had approximately 50 ml of PAS-E added on Day 3 of storage. Its unmodified twin served as a control. Each adult d... In the nine randomly selected collections, pH on Day 8 was approximately 0.4 units higher in the test units. Platelet activation tended to be lower, with CD62P surface expression on Day 8 of 54.6 ± 9.... The addition of 20% PAS-E by volume increased the buffering capacity of the units whilst maintaining other in vitro storage characteristics....

Blood Platelets Blood Preservation Humans Infant, Newborn Plasma +2 autres

Antienzymes : Questions médicales fréquentes

Termes MeSH sélectionnés :

Questions fréquentes et termes MeSH associés

Diagnostic 5

Symptômes 5

Prévention 5

Traitements 5

Complications 5

Facteurs de risque 5

Contenu validé par Dr Olivier Menir

Sous-catégories

Inhibiteurs des protéines activatrices de la 5-lipoxygénase

Inhibiteurs de l'acétaldéhyde déshydrogénase

Inhibiteurs de l'adénosine désaminase

Inhibiteurs des adénylate cyclases

Inhibiteurs de la calcineurine

Inhibiteurs de l'anhydrase carbonique

Inhibiteurs et modulateurs de la gamma-secrétase

Inhibiteurs des enzymes du cytochrome P-450

Antifoliques

Inhibiteurs de désacétylase d'histone

Inhibiteurs de l'intégrase

Inhibiteurs de la lipoxygénase

Inhibiteurs de la monoamine oxydase

Inhibiteurs de la synthèse d'acide nucléique

Inhibiteurs de l'ornithine décarboxylase

Inhibiteurs de la phosphodiestérase

Inhibiteurs des phosphoinositide-3 kinases

Inhibiteurs de la phospholipase A2

Inhibiteurs de prolyle hydroxylases

Inhibiteurs de protéases

Inhibiteurs de protéines kinases

Inhibiteurs de la synthèse protéique

Inhibiteurs de la pompe à protons

Agents découplants

Inhibiteurs du cytochrome P-450 CYP1A2

Inhibiteurs du cytochrome P-450 CYP2B6

Inhibiteurs du cytochrome P-450 CYP2C8

Inhibiteurs du cytochrome P-450 CYP2C19

Inhibiteurs du cytochrome P-450 CYP2C9

Inhibiteurs du cytochrome P-450 CYP2D6

Inhibiteurs du cytochrome P-450 CYP2E1

Inhibiteurs du cytochrome P-450 CYP3A

Inhibiteurs de la phosphodiestérase-3

Inhibiteurs de la phosphodiestérase-4

Inhibiteurs de la phosphodiestérase-5

Inhibiteurs de l'enzyme de conversion de l'angiotensine

Inhibiteurs de la cystéine protéinase

Inhibiteurs de métalloprotéinases matricielles

Inhibiteurs du protéasome

Inhibiteurs de la rénine

Inhibiteurs de la sérine protéinase

Inhibiteurs des Janus kinases

Inhibiteurs de protéine-tyrosine kinase

Inhibiteurs des vasopeptidases

Inhibiteurs des caspases

Inhibiteurs de serine peptidase de type Kazal

Serpines

Inhibiteurs trypsiques

Auteurs principaux

Sources (25 au total)